1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,430 | 3,475 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: IDE034, ein bispezifisches ADC, das von Biocytogen an IDEAYA lizenziert wurde, erhält IND-Zulassung von der FDA | 209 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), gab bekannt, dass sein Partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), ein Unternehmen für Präzisionsonkologie, die Genehmigung... ► Artikel lesen | |
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Fr | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance | 922 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance... ► Artikel lesen | |
| Fr | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BUSINESS PARTNER IDEAYA RECEIVED FDA CLEARANCE OF IND APPLICATION FOR IDE034 | 1 | HKEx | ||
| 26.11. | BIOCYTOGEN-B (02315): INSIDE INFORMATION DETERMINATION OF THE OFFER SIZE AND OFFER PRICE FOR THE A SHARE OFFERING | 1 | HKEx | ||
| 19.11. | BIOCYTOGEN-B (02315): INSIDE INFORMATION THE PROGRESS OF PROPOSED ISSUE OF A SHARES FINANCIAL INFORMATION IN RELATION TO A SHARE PROSPECTUS | 1 | HKEx | ||
| 19.11. | BIOCYTOGEN-B (02315): INSIDE INFORMATION PRELIMINARY PRICE CONSULTATION PERIOD FOR THE PROPOSED ISSUE OF A SHARE AND SUMMARY OF PRINCIPAL PROVISIONS OF ... | 1 | HKEx | ||
| 19.11. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING HELD ON 19 NOVEMBER 2025 | 1 | HKEx | ||
| 03.11. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE USE AT THE 2025 FIRST EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, NOVEMBER 19, 2025 | - | HKEx | ||
| 03.11. | BIOCYTOGEN-B (02315): NOTICE OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 03.11. | BIOCYTOGEN-B (02315): (1) PROPOSED ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTIONS (2) PROPOSED AMENDMENTS TO THE ... | 1 | HKEx | ||
| 16.10. | BIOCYTOGEN-B (02315): ANNOUNCEMENT ON APPROVAL OF REGISTRATION OF THE ISSUE OF A SHARE BY CSRC | 1 | HKEx | ||
| 25.09. | BIOCYTOGEN-B (02315): 2025 INTERIM REPORT | - | HKEx | ||
| 24.09. | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT ON APPROVAL OF THE PROPOSED ISSUE OF A SHARES BY THE LISTING COMMITTEE OF SCI-TECH BOARD OF THE ... | 1 | HKEx | ||
| 17.09. | BIOCYTOGEN-B (02315): INSIDE INFORMATION THE PROGRESS OF PROPOSED ISSUE OF A SHARES | 1 | HKEx | ||
| 17.09. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen gibt bekannt, dass der ADC-Innovator Tubulis einen weltweiten Exklusivlizenzvertrag für einen Einzelantikörper unterzeichnet hat | 348 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), ein globales Biotechnologieunternehmen, das die Forschung und Entwicklung neuartiger Antikörper-basierter Medikamente mit... ► Artikel lesen | |
| 16.09. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody | 418 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies... ► Artikel lesen | |
| 04.09. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Vereinbarung mit Merck, KGaA, Darmstadt, Deutschland, zur Weiterentwicklung von Antikörper-konjugierten Lipid-basierten Verabreichungslösungen | 671 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315, ein globales Biotechnologieunternehmen, das die Forschung und Entwicklung neuartiger Antikörper-basierter Medikamente mit... ► Artikel lesen | |
| 04.09. | Biocytogen, Merck KGaA To Develop Targeted Nucleic Acid Delivery Via Antibody-Conjugated LNPs | 705 | AFX News | BERLIN (dpa-AFX) - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and Merck KGaA (MKKGY, MRCG.DE, MRK.MI)
announced that they have entered into an evaluation and option agreement to advance... ► Artikel lesen | |
| 04.09. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions | 710 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies... ► Artikel lesen | |
| 28.08. | BIOCYTOGEN-B (02315): TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE | 1 | HKEx |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,027 | -6,16 % | MEDIGENE AG stürzt ab - ich warne vor dem nächsten Desaster! | ||
| BIOFRONTERA | 2,750 | +1,48 % | Biofrontera schließt Phase-1-Studie für erweitertes Anwendungsgebiet von Ameluz ab | ||
| CLINUVEL | 6,755 | -1,17 % | Clinuvel Targets 2026 Filing for Neuracthel | ||
| EDITAS MEDICINE | 2,120 | +2,66 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| ASEP MEDICAL | 6,021 | -100,00 % | ASEP Medical Holdings Inc (2): ASEP licenses anti-biofilm peptide tech to Bondent | ||
| CELLECTAR BIOSCIENCES | 3,790 | -0,26 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,864 | +2,53 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| CLEAN HARBORS | 203,00 | -0,39 % | Why Clean Harbors Stock Triumphed on Tuesday | ||
| SPERO THERAPEUTICS | 1,972 | +1,34 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
| MESOBLAST | 1,460 | +4,29 % | MESOBLAST LTD - 6-K, Report of foreign issuer | ||
| CSTONE PHARMACEUTICALS | 0,610 | -1,61 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - EUROPEAN COMMISSION APPROVED SUGMALIMAB FOR STAGE III NON-SMALL CELL LUNG CANCER | ||
| PROTALIX BIOTHERAPEUTICS | 1,460 | -2,01 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EST
CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:... ► Artikel lesen | |
| LIR LIFE SCIENCES | 0,696 | +19,18 % | Lir Life Sciences Corp.: Lir Life Sciences Announces Engagement for IR Services | VANCOUVER, BC / ACCESS Newswire / November 26, 2025 / Lir Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has engaged MCS Market Communication... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 80,50 | -6,94 % | BTIG initiates coverage on Palvella Therapeutics stock with Buy rating | ||
| PURPLE BIOTECH | 0,831 | -2,10 % | Purple Biotech Ltd.: Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress |
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,485 Euro und damit +2,05 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.